Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
7.19
-0.05 (-0.69%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Zevra Therapeutics Employees
Zevra Therapeutics had 59 employees as of December 31, 2024. The number of employees decreased by 10 or -14.49% compared to the previous year.
Employees
59
Change (1Y)
-10
Growth (1Y)
-14.49%
Revenue / Employee
$400,203
Profits / Employee
-$1,788,322
Market Cap
389.63M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
ZVRA News
- 8 days ago - Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism - GlobeNewsWire
- 18 days ago - Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million - GlobeNewsWire
- 25 days ago - Zevra Therapeutics Files Preliminary Proxy - GlobeNewsWire
- 6 weeks ago - Zevra Therapeutics, Inc. (ZVRA) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Zevra Reports Full Year 2024 and Fourth Quarter Financial Results - GlobeNewsWire
- 2 months ago - Zevra Launches New Disease State Awareness Campaign, ‘Learn NPC, Read Between the Signs,' to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C - GlobeNewsWire
- 2 months ago - Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million - GlobeNewsWire
- 2 months ago - Zevra to Report 2024 Fourth Quarter and Full Year Financial Results - GlobeNewsWire